mk-4621
mAbexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 25, 2017 (NCT03065023)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
PLAAT4 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- rgt100
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03739138 | Phase 1 | Dec 18, 2018 | Merck |
| NCT03065023 | Phase 1/Phase 2 (Phase 2) | Apr 25, 2017 | Rigontec GMBH, University of Oxford |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 1 | 1 | 1 | 2018 |
| Rigontec GMBH | For profit | 1 | 1 | 1 | 2017 |
| University of Oxford | Academic/Hospital | 1 | 0 | 1 | 2017 |
3 organizations
Page 1 / 1